Involvement of c-Jun NH2 terminal kinase and p38MAPK in rapamycin-mediated inhibition of neointimal formation in rat carotid arteries

J Cardiovasc Pharmacol. 2005 Oct;46(4):519-25. doi: 10.1097/01.fjc.0000179001.00779.a5.

Abstract

Objective: Rapamycin-coated stents in coronary artery lesions have recently been shown to be effective in inhibiting neointimal formation. However, little is known about the effects of rapamycin on mitogen-activated protein kinase (MAPK), which is an important signal for neointimal formation. Therefore, we examined the effects of rapamycin on MAPK and transcriptional factors in cultured human coronary artery smooth muscle cells (CASMC) and in balloon-injured rat carotid arteries.

Methods and results: Activation of ERK, JNK, p38MAPK, AP-1, and NF-kB in coronary artery smooth muscle cells was increased by 2% fetal bovine serum. Ten nmol/L of rapamycin prevented the activation of JNK, p38MAPK, AP-1, and NF-kB (65%, 65%, 67%, and 26% respectively, P<0.01). In an in vivo study, remarkable neointimal formation was observed 14 days after injury. Coating Pluronic gel with 20 and 50 mug rapamycin around the injured artery significantly decreased the intimal area/medial area ratio, compared with vehicle (0.75 vs. 1.2, P<0.01). Rapamycin prevented the increase in activation of JNK, p38MAPK, AP-1, and NF-kB in injured artery (42%, 70%, 75%, and 60% respectively, P<0.05).

Conclusions: Neointimal formation after balloon injury is inhibited by rapamycin, which is partially mediated by inhibition of JNK and p38MAPK, followed by AP-1 and NF-kB.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carotid Artery Injuries / enzymology
  • Carotid Artery Injuries / metabolism
  • Carotid Artery, Common / drug effects*
  • Carotid Artery, Common / enzymology
  • Carotid Artery, Common / metabolism
  • Cell Proliferation / drug effects
  • Coronary Vessels / drug effects
  • Coronary Vessels / enzymology
  • Immunosuppressive Agents / pharmacology*
  • JNK Mitogen-Activated Protein Kinases / metabolism*
  • Male
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / enzymology
  • Muscle, Smooth, Vascular / metabolism
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / enzymology
  • NF-kappa B / metabolism
  • Rats
  • Rats, Wistar
  • Sirolimus / pharmacology*
  • Transcription Factor AP-1 / metabolism
  • Tunica Intima / drug effects*
  • Tunica Intima / enzymology
  • Tunica Intima / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Immunosuppressive Agents
  • NF-kappa B
  • Transcription Factor AP-1
  • JNK Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • Sirolimus